SCHEMBL5189459

SCHEMBL5189459

O=C(O)[C@H](Cc1ccccc1)NS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 11/20 0.73
MMP9 P14780 9/20 0.73
ADAMTS4 O75173 1/20 0.73
ALDH1A1 P00352 2/20 0.65
ADAMTS5 Q9UNA0 1/20 0.65
MAPT P10636 1/20 0.65
MMP1 P03956 1/20 0.65
MMP3 P08254 1/20 0.65
MMP7 P09237 1/20 0.65
MMP13 P45452 1/20 0.65
POLB P06746 1/20 0.62
L3MBTL1 Q9Y468 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CA2 P00918 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26616346 1.00 MMP2 (0.73) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL26616349 1.00 MMP2 (0.73) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL8919459 0.93 MMP2 (0.63) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL8448000 0.90 MMP2 (0.59) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL8593032 0.90 MMP2 (0.59) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL8141491 0.89 TDP1 (0.72) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL8141494 0.89 TDP1 (0.72) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL8578884 0.89 MMP2 (0.57) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL7292784 0.87 F2 (0.57) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5
SCHEMBL7289803 0.86 ITGB3 (0.59) MMP2MMP9ADAMTS4ALDH1A1ADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289810-A1 Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments MAM-AGE S.R.L. (IT) 2025-09-18 US disclosed
WO-2023209109-A1 COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND THEIR USE AS MEDICAMENTS MAM - AGE S.R.L. (IT) 2023-11-02 WO disclosed
EP-1377542-B1 HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES AMBRILIA BIOPHARMA INC (CA) 2007-08-01 EP disclosed
EP-1803706-A1 HIV protease inhibitors based on amino acid derivatives Ambrilia Biopharma Inc. (CA) 2007-07-04 EP disclosed
US-6677367-B2 LYSINE DERIVATIVE WITH 2-AMINOSULFONYLTHIOPHENE SUBSTITUENT; ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) VIRICIDES PHARMACOR INC. (CA) 2004-01-13 US disclosed
EP-1377542-A1 HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES Pharmacor Inc. (CA) 2004-01-07 EP disclosed
US-6656965-B2 In particular N-epsilon-amino acid substituted L-lysine derivatives possessing aspartyl protease inhibitory properties. PHARMACOR INC. (CA) 2003-12-02 US disclosed
US-20030195159-A1 HIV protease inhibitors based on amino acid derivatives TAIMED BIOLOGICS, INC. (TW) 2003-10-16 US disclosed
US-6610689-B2 Viricides PHARMACOR INC. (CA) 2003-08-26 US disclosed
US-6608100-B1 N-epsilon-amino acid substituted L-lysine sulfonamide derivatives possessing aspartyl protease inhibitory properties PHARMACOR INC. (CA) 2003-08-19 US disclosed
US-20030144265-A1 HIV protease inhibitors based on amino acid derivatives TAIMED BIOLOGICS, INC. (TW) 2003-07-31 US disclosed
US-20030119803-A1 HIV protease inhibitors based on amino acid derivatives TAIMED BIOLOGICS, INC. (TW) 2003-06-26 US disclosed
US-6506786-B2 Such as N-isobutyl-N-(4-methylbenzene-sulfonyl)-N-(N-(4-methylbenzenesulfonyl)-L -phenylalanyl)-L-lysine PHARMACOR INC. (CA) 2003-01-14 US disclosed
US-20020151546-A1 HIV protease inhibitors based on amino acid derivatives TAIMED BIOLOGICS, INC. (TW) 2002-10-17 US disclosed
WO-2002064551-A1 HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES PHARMACOR INC. (CA) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144265-A1 HIV protease inhibitors based on amino acid derivatives ANPEP, PEPD, XPNPEP1 MMP2 845/4885MMP9 732/4885ADAMTS4 4020/4885
US-20020151546-A1 HIV protease inhibitors based on amino acid derivatives ANPEP, PEPD, XPNPEP1 MMP2 845/4885MMP9 732/4885ADAMTS4 4020/4885
US-20030195159-A1 HIV protease inhibitors based on amino acid derivatives ANPEP, PEPD, XPNPEP1 MMP2 845/4885MMP9 732/4885ADAMTS4 4020/4885
US-20250289810-A1 Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments NLRP3, NLRP1, IL18 MMP2 1807/4885MMP9 1030/4885ADAMTS4 2371/4885
US-20030119803-A1 HIV protease inhibitors based on amino acid derivatives ANPEP, PEPD, XPNPEP1 MMP2 845/4885MMP9 732/4885ADAMTS4 4020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.